|
1
|
Yuan A, Yu CJ, Chen WJ, Lin FY, Kuo SH,
Luh KT and Yang PC: Correlation of total VEGF mRNA and protein
expression with histologic type, tumor angiogenesis, patient
survival and timing of relapse in non-small-cell lung cancer. Int J
Cancer. 89:475–483. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Han H, Silverman JF, Santucci TS, et al:
Vascular endothelial growth factor expression in stage I non-small
cell lung cancer correlates with neoangiogenesis and a poor
prognosis. Ann Surg Oncol. 8:72–79. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kaya A, Ciledag A, Gulbay BE, et al: The
prognostic significance of vascular endothelial growth factor
levels in sera of non-small cell lung cancer patients. Respir Med.
98:632–636. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jain L, Vargo CA, Danesi R, Sissung TM,
Price DK, Venzon D, Venitz J and Figg WD: The role of vascular
endothelial growth factor SNPs as predictive and prognostic markers
for major solid tumors. Mol Cancer Ther. 8:2496–2508. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Brogan IJ, Khan N, Isaac K, Hutchinson JA,
Pravica V and Hutchinson IV: Novel polymorphisms in the promoter
and 5′ UTR regions of the human vascular endothelial growth factor
gene. Hum Immunol. 60:1245–1249. 1999.
|
|
6
|
Tischer E, Mitchell R, Hartman T, Silva M,
Gospodarowicz D, Fiddes JC and Abraham JA: The human gene for
vascular endothelial growth factor. Multiple protein forms are
encoded through alternative exon splicing. J Biol Chem.
266:11947–11954. 1991.PubMed/NCBI
|
|
7
|
Stevens A, Soden J, Brenchely PE, Ralph S
and Ray DW: Haplotype analysis of the polymorphic human vascular
endothelial growth factor gene promoter. Cancer Res. 63:812–816.
2003.PubMed/NCBI
|
|
8
|
Watson CJ, Webb NJ, Bottomley MJ and
Brenchley PE: Identification of polymorphisms within the vascular
endothelial growth factor (VEGF) gene: correlation with variation
in VEGF protein production. Cytokine. 12:1232–1235. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lin CC, Wu HC, Tsai FJ, Chen HY and Chen
WC: Vascular endothelial growth factor gene-460 C/T polymorphism is
a biomarker for prostate cancer. Urology. 62:374–377. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ku KT, Wan L, Peng HC, Tsai MH, Tsai CH
and Tsai FJ: Vascular endothelial growth factor gene-460 C/T
polymorphism is a biomarker for oral cancer. Oral Oncol.
41:497–502. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lu H, Shu XO, Cui Y, et al: Association of
genetic polymorphisms in the VEGF gene with breast cancer survival.
Cancer Res. 65:5015–5019. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kim JG, Chae YS, Sohn SK, et al: Vascular
endothelial growth factor gene polymorphisms associated with
prognosis for patients with colorectal cancer. Clin Cancer Res.
14:62–66. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Heist RS, Zhai R, Liu G, et al: VEGF
polymorphisms and survival in early-stage non-small-cell lung
cancer. J Clin Oncol. 26:856–862. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhai R, Liu G, Zhou W, et al: Vascular
endothelial growth factor genotypes, haplotypes, gender, and the
risk of non-small cell lung cancer. Clin Cancer Res. 14:612–617.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Masago K, Fujita S, Kim YH, et al: Effect
of vascular endothelial growth factor polymorphisms on survival in
advanced-stage non-small-cell lung cancer. Cancer Sci.
100:1917–1922. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ferrara N: VEGF and the quest for tumour
angiogenesis factors. Nat Rev Cancer. 2:795–803. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Forsythe JA, Jiang BH, Iyer NV, Agani F,
Leung SW, Koos RD and Semenza GL: Activation of vascular
endothelial growth factor gene transcription by hypoxia-inducible
factor 1. Mol Cell Biol. 16:4604–4613. 1996.PubMed/NCBI
|
|
18
|
Thurston G, Noguera-Troise I and
Yancopoulos GD: The Delta paradox: DLL4 blockade leads to more
tumour vessels but less tumour growth. Nat Rev Cancer. 7:327–331.
2007. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Indraccolo S, Minuzzo S, Masiero M, et al:
Cross-talk between tumor and endothelial cells involving the
Notch3-Dll4 interaction marks escape from tumor dormancy. Cancer
Res. 69:1314–1323. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Patel NS, Li JL, Generali D, Poulsom R,
Cranston DW and Harris AL: Up-regulation of delta-like 4 ligand in
human tumor vasculature and the role of basal expression in
endothelial cell function. Cancer Res. 65:8690–8697. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hainaud P, Contrerès JO, Villemain A, Liu
LX, Plouët J, Tobelem G and Dupuy E: The role of the vascular
endothelial growth factor-Delta-like 4 ligand/Notch4-ephrin B2
cascade in tumor vessel remodeling and endothelial cell functions.
Cancer Res. 66:8501–8510. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Patel NS, Dobbie MS, Rochester M, Steers
G, Poulsom R, Le Monnier K, Cranston DW, Li JL and Harris AL:
Up-regulation of endothelial delta-like 4 expression correlates
with vessel maturation in bladder cancer. Clin Cancer Res.
12:4836–4844. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fontanini G, Vignati S, Boldrini L, et al:
Vascular endothelial growth factor is associated with
neovascularization and influences progression of non-small cell
lung carcinoma. Clin Cancer Res. 3:861–865. 1997.PubMed/NCBI
|
|
24
|
Giatromanolaki A, Koukourakis MI, Sivridis
E, et al: Relation of hypoxia inducible factor 1 alpha and 2 alpha
in operable non-small cell lung cancer to angiogenic/molecular
profile of tumours and survival. Br J Cancer. 85:881–890. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Martinez JC, Müller MM, Turley H, et al:
Nuclear and membrane expression of the angiogenesis regulator
delta-like ligand 4 (DLL4) in normal and malignant human tissues.
Histopathology. 54:598–606. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Donnem T, Andersen S, Al-Shibli K, Al-Saad
S, Busund LT and Bremnes RM: Prognostic impact of Notch ligands and
receptors in nonsmall cell lung cancer: coexpression of Notch-1 and
vascular endothelial growth factor-A predicts poor survival.
Cancer. 116:5676–5685. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tzanakis N, Gazouli M, Rallis G, et al:
Vascular endothelial growth factor polymorphisms in gastric cancer
development, prognosis, and survival. J Surg Oncol. 94:624–630.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hefler LA, Mustea A, Könsgen D, et al:
Vascular endothelial growth factor gene polymorphisms are
associated with prognosis in ovarian cancer. Clin Cancer Res.
13:898–901. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Koukourakis MI, Papazoglou D,
Giatromanolaki A, Bougioukas G, Maltezos E and Sivridis E: VEGF
gene sequence variation defines VEGF gene expression status and
angiogenic activity in non-small cell lung cancer. Lung Cancer.
46:293–298. 2004. View Article : Google Scholar : PubMed/NCBI
|
